{"id":46806,"date":"2022-08-01T22:01:41","date_gmt":"2022-08-01T20:01:41","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-report-second-quarter-2022-financial-results-and-provide-corporate-update-on-august-9-2022\/"},"modified":"2022-08-01T22:01:41","modified_gmt":"2022-08-01T20:01:41","slug":"arcturus-therapeutics-to-report-second-quarter-2022-financial-results-and-provide-corporate-update-on-august-9-2022","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-report-second-quarter-2022-financial-results-and-provide-corporate-update-on-august-9-2022\/","title":{"rendered":"\u00a0Arcturus Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 9, 2022"},"content":{"rendered":"
\n

SAN DIEGO–(BUSINESS WIRE)–$ARCT<\/a> #ClinicalTrial<\/a>–Arcturus Therapeutics Holdings Inc. (the \u201cCompany\u201d, \u201cArcturus\u201d, Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended June 30, 2022 after the market close on Tuesday, August 9 and will also host a conference call and webcast at 4:30 pm Eastern Daylight Time on August 9, 2022.\n<\/p>\n

<\/a><\/p>\n

\nTuesday, August 9, 2022 @ 4:30 pm EDT
\n
<\/b>Domestic: 1-800-263-0877
\n
International: 1-323-794-2094
\n
Conference ID: 8017918
\n
Webcast: Link<\/a>\n<\/p>\n

\nAbout Arcturus Therapeutics<\/b>\n<\/p>\n

\nFounded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global late-stage clinical mRNA medicines and vaccines company with enabling technologies: (i) LUNAR\u00ae lipid-mediated delivery, (ii) STARR\u2122 mRNA Technology (samRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus\u2019 diverse pipeline of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat ornithine transcarbamylase (OTC) deficiency, and cystic fibrosis, along with partnered programs including glycogen storage disease type III, and hepatitis B virusArcturus\u2019 versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus\u2019 technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China and other countries). Arcturus\u2019 commitment to the development of novel RNA therapeutics has led to collaborations including, amongst others, Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., and the Cystic Fibrosis Foundation. addition, please connect with us on Twitter and LinkedIn. For more information visit www.ArcturusRx.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nIR and Media Contacts<\/b>
Arcturus Therapeutics
\n
IR@arcturusrx.com<\/a>\n<\/p>\n

\nKendall Investor Relations
\n
Carlo Tanzi, Ph.D.
\n
(617) 914-0008
\n
ctanzi@kendallir.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN DIEGO–(BUSINESS WIRE)–$ARCT #ClinicalTrial–Arcturus Therapeutics Holdings Inc. (the \u201cCompany\u201d, \u201cArcturus\u201d, Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended June 30, 2022 after the … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46806","6":"format-standard","7":"category-industry"},"yoast_head":"\n\u00a0Arcturus Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 9, 2022 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-report-second-quarter-2022-financial-results-and-provide-corporate-update-on-august-9-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u00a0Arcturus Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 9, 2022 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO–(BUSINESS WIRE)–$ARCT #ClinicalTrial–Arcturus Therapeutics Holdings Inc. (the \u201cCompany\u201d, \u201cArcturus\u201d, Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended June 30, 2022 after the ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-report-second-quarter-2022-financial-results-and-provide-corporate-update-on-august-9-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-01T20:01:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220801005045\/en\/837248\/21\/arcturus-logo-blueback.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arcturus-therapeutics-to-report-second-quarter-2022-financial-results-and-provide-corporate-update-on-august-9-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arcturus-therapeutics-to-report-second-quarter-2022-financial-results-and-provide-corporate-update-on-august-9-2022\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"\u00a0Arcturus Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 9, 2022\",\"datePublished\":\"2022-08-01T20:01:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arcturus-therapeutics-to-report-second-quarter-2022-financial-results-and-provide-corporate-update-on-august-9-2022\\\/\"},\"wordCount\":330,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arcturus-therapeutics-to-report-second-quarter-2022-financial-results-and-provide-corporate-update-on-august-9-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220801005045\\\/en\\\/837248\\\/21\\\/arcturus-logo-blueback.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arcturus-therapeutics-to-report-second-quarter-2022-financial-results-and-provide-corporate-update-on-august-9-2022\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arcturus-therapeutics-to-report-second-quarter-2022-financial-results-and-provide-corporate-update-on-august-9-2022\\\/\",\"name\":\"\u00a0Arcturus Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 9, 2022 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arcturus-therapeutics-to-report-second-quarter-2022-financial-results-and-provide-corporate-update-on-august-9-2022\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arcturus-therapeutics-to-report-second-quarter-2022-financial-results-and-provide-corporate-update-on-august-9-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220801005045\\\/en\\\/837248\\\/21\\\/arcturus-logo-blueback.jpg\",\"datePublished\":\"2022-08-01T20:01:41+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arcturus-therapeutics-to-report-second-quarter-2022-financial-results-and-provide-corporate-update-on-august-9-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arcturus-therapeutics-to-report-second-quarter-2022-financial-results-and-provide-corporate-update-on-august-9-2022\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arcturus-therapeutics-to-report-second-quarter-2022-financial-results-and-provide-corporate-update-on-august-9-2022\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220801005045\\\/en\\\/837248\\\/21\\\/arcturus-logo-blueback.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220801005045\\\/en\\\/837248\\\/21\\\/arcturus-logo-blueback.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arcturus-therapeutics-to-report-second-quarter-2022-financial-results-and-provide-corporate-update-on-august-9-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u00a0Arcturus Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 9, 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u00a0Arcturus Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 9, 2022 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-report-second-quarter-2022-financial-results-and-provide-corporate-update-on-august-9-2022\/","og_locale":"en_US","og_type":"article","og_title":"\u00a0Arcturus Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 9, 2022 - Pharma Trend","og_description":"SAN DIEGO–(BUSINESS WIRE)–$ARCT #ClinicalTrial–Arcturus Therapeutics Holdings Inc. (the \u201cCompany\u201d, \u201cArcturus\u201d, Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended June 30, 2022 after the ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-report-second-quarter-2022-financial-results-and-provide-corporate-update-on-august-9-2022\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-01T20:01:41+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220801005045\/en\/837248\/21\/arcturus-logo-blueback.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-report-second-quarter-2022-financial-results-and-provide-corporate-update-on-august-9-2022\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-report-second-quarter-2022-financial-results-and-provide-corporate-update-on-august-9-2022\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"\u00a0Arcturus Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 9, 2022","datePublished":"2022-08-01T20:01:41+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-report-second-quarter-2022-financial-results-and-provide-corporate-update-on-august-9-2022\/"},"wordCount":330,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-report-second-quarter-2022-financial-results-and-provide-corporate-update-on-august-9-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220801005045\/en\/837248\/21\/arcturus-logo-blueback.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-report-second-quarter-2022-financial-results-and-provide-corporate-update-on-august-9-2022\/","url":"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-report-second-quarter-2022-financial-results-and-provide-corporate-update-on-august-9-2022\/","name":"\u00a0Arcturus Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 9, 2022 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-report-second-quarter-2022-financial-results-and-provide-corporate-update-on-august-9-2022\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-report-second-quarter-2022-financial-results-and-provide-corporate-update-on-august-9-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220801005045\/en\/837248\/21\/arcturus-logo-blueback.jpg","datePublished":"2022-08-01T20:01:41+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-report-second-quarter-2022-financial-results-and-provide-corporate-update-on-august-9-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-report-second-quarter-2022-financial-results-and-provide-corporate-update-on-august-9-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-report-second-quarter-2022-financial-results-and-provide-corporate-update-on-august-9-2022\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220801005045\/en\/837248\/21\/arcturus-logo-blueback.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220801005045\/en\/837248\/21\/arcturus-logo-blueback.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/arcturus-therapeutics-to-report-second-quarter-2022-financial-results-and-provide-corporate-update-on-august-9-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"\u00a0Arcturus Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 9, 2022"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46806","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46806"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46806\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46806"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46806"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46806"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}